KR102176811B1 - Composition for promoting hair growth - Google Patents

Abstract

Since the peptide of the present invention has excellent efficacy in promoting hair growth, a composition comprising the same can be used for promoting hair growth or preventing, improving, and treating hair loss.

Description

Composition for promoting hair growth {COMPOSITION FOR PROMOTING HAIR GROWTH}

The present invention relates to a composition for promoting hair growth comprising a peptide having an excellent hair growth promoting effect.

Recently, as interest in beauty has increased, interest in hair loss treatment is also increasing. Hair does not have a direct important physiological function to life, but it buffers against external shocks, blocks UV rays, protects the human body from external irritation, and absorbs heavy metals such as arsenic, mercury, and zinc that are unnecessary to the body and discharges them out of the body. have. Hair is divided into a growth phase (anagen) in which the hair grows, a catagen phase in which the metabolic process is delayed as the growth stops and the hair bulb is reduced, and a telogen, in which the hair roots are pushed upward as the hair follicle is contracted and the hair falls out. As new hairs are created in the same place, old hairs fall off and have a hair cycle that converts to a growing phase, and growth and dropping are repeated throughout life.

Hair loss is the condition where such hair is not normally located, and its causes include decrease in follicle function due to male hormone involvement, decrease in scalp physiological function, local blood flow disorder due to scalp tension, malnutrition, stress, side effects from drugs. , Genetic factors, chemicals, leukemia, tuberculosis, malignant lymphoma and other diseases. In addition to the above functions, if hair loss is severe, there may be a problem in social life, and it may have a serious effect due to psychological atrophy, so hair loss treatment is very important in terms of quality of life.

Currently, the most widely used methods for hair loss treatment include self-transplantation using one's own hair, and drug treatment using minoxidil and Propecia. In the case of minoxidil, increased nutrient supply to the hair cells through vasodilation and the effect of opening a potassium channel induces hair growth, and in the case of Propecia, it induces hair growth by inhibiting the production of dihydrotestosterone (DHT). , When both of these drugs are treated, hair growth is effective, but when treatment is stopped, hair loss progresses again and the effect of preventing hair loss is greater than that of hair growth.Propecia has sexual dysfunction, and pregnant women have birth defects. The same side effects can occur. Recently, gene therapy, which is performed by transferring genes related to hair loss to hair follicles or blocking gene expression, has been developed, but there is a problem in that the efficacy and safety of the treatment are uncertain, and the treatment cost is high, so clinical application is not easy.

Meanwhile, recently, a method of treating hair loss using stem cells has also been attempted, but there is currently no method of treating hair loss using stem cells, and the method under study includes a method of regenerating hair follicles by injecting dermal papilla cells with epithelial cells. Since it is reproduced at the level of animal testing, a lot of research is still needed as a treatment. In order to improve this problem, attempts have been made to treat hair loss using a culture medium produced when culturing stem cells rather than stem cells, but it has not yet achieved the effectiveness at the level of commercialization. I am verifying.

Korean Patent No. 1570004

An object of the present invention is to provide a peptide having an excellent hair growth promoting effect and a composition comprising the same.

1. A peptide comprising the sequence of SEQ ID NO: 1 or 2 and consisting of 50 or less amino acid residues.

2. A composition for promoting hair growth comprising the peptide of 1 above.

3. A pharmaceutical composition for promoting hair growth comprising the peptide of 1 above.

4. Cosmetic composition for promoting hair growth comprising the peptide of 1 above.

5. Health functional food for promoting hair growth containing the peptide of 1 above.

The peptide of the present invention has excellent efficacy in promoting hair growth, and a composition comprising the same can be used for promoting hair growth or for preventing or treating hair loss.

1 is a negative control group, a positive control group, an experimental group treated with a peptide consisting of the amino acid sequence of SEQ ID NO: 1 (DPS-4), an experimental group treated with a peptide consisting of the amino acid sequence of SEQ ID NO: 2 (DPS-5), and SEQ ID NO: 3 This is a photograph of the appearance of the hair growth degree of the experimental group treated with the peptide (DPS-8) consisting of the amino acid sequence of.
2 is a negative control group, a positive control group, an experimental group treated with a peptide consisting of the amino acid sequence of SEQ ID NO: 1 (DPS-4), an experimental group treated with a peptide consisting of the amino acid sequence of SEQ ID NO: 2 (DPS-5), and SEQ ID NO: 3 This is the result of histological observation of the hair growth degree of the experimental group treated with the peptide (DPS-8) consisting of the amino acid sequence of.

Hereinafter, the present invention will be described in detail.

The present invention provides a peptide comprising the sequence of SEQ ID NO: 1 or 2 and consisting of 50 or less amino acid residues.

A peptide comprising the amino acid sequence of SEQ ID NO: 1 (CLEYFKGAIPLRK) or the amino acid sequence of SEQ ID NO: 2 (KRVKNAVKYLQ) and consisting of 50 or less amino acid residues can be chemically synthesized. When prepared by chemical synthesis, it can be prepared by chemical synthesis (Creighton, Proteins; Structures and Molecular Principles, WH Freeman and Co., NY, 1983) well known in the art. Representative methods include, but are not limited to, liquid or solid phase synthesis, fragment condensation, F-MOC or T-BOC chemistry. (Chemical Approaches to the Synthesis of Peptides and Proteins, Williams et al ., Eds., CRC Press, Boca Raton Florida, 1997; A Practical Approach, Atherton & Sheppard, Eds., IRL Press, Oxford, England, 1989).

In addition, the peptide of the present invention may be prepared by a genetic engineering method, but is not limited to the following method. First, a DNA sequence encoding the peptide is prepared according to a conventional method. DNA sequences can be prepared by PCR amplification using appropriate primers. Alternatively, DNA sequences may be synthesized by standard methods known in the art, for example, using an automatic DNA synthesizer (eg, those sold by Biosearch or Applied iosystems). The produced DNA sequence is operably linked to this DNA sequence and inserted into a vector containing one or more expression control sequences (eg, promoters, enhancers, etc.) that control the expression of the DNA sequence, and recombinant expression formed therefrom The host cell is transformed with the vector. The resulting transformant is cultured under a medium and conditions appropriate to allow the DNA sequence to be expressed, to recover a substantially pure peptide encoded by the DNA sequence from the culture. The recovery can be performed using a method known in the art (eg, chromatography). In the above, "substantially pure peptide" means that the peptide according to the present invention does not substantially contain any other protein derived from a host. The genetic engineering method for synthesizing the peptides of the present invention may be referred to the following literature: Maniatis et al ., Molecular Cloning; A laboratory Manual, Cold Spring Harbor laboratory, 1982; Sambrook et al ., Molecular Cloning: A Laboratory Manual, ColdSpring Harbor Press, NY, Second (1998) and Third (2000) Edition; Gene Expression Technology, Method in Enzymology, Genetics and Molecular Biology, Method in Enzymology, Guthrie & Fink (eds.), Academic Press, San Diego, Calif, 1991; Hitzeman et al ., J. Biol. Chem, 255:. 12073 - 12080 , 1990.

The peptide of the present invention is composed of a sequence of 50 or less amino acids, specifically 50 or less, 45 or less, 40 or less, 35 or less, 30 or less, 25 or less, 20 or less, or 15 or less. There may be several amino acid residues additionally linked to the N-terminus or C-terminus of the amino acid sequence of SEQ ID NO: 1 or 2.

Peptides of the present invention have the advantage of being relatively short in length compared to peptides consisting of a long amino acid sequence for the same purpose, so that they are easily absorbed in the body, and in particular, have a good transdermal absorption rate, so that the efficacy of the peptide can be maximized.

The peptide of the present invention may include the sequence of SEQ ID NO: 1 or 2, and may include functional equivalents and variants of the peptide consisting of 50 or less amino acid residues.

The functional equivalent of the peptide includes a peptide that does not change the activity of the peptide as a whole, and peptides capable of functionally performing the same function are included in the scope of the present invention. The variant is, for example, one or several amino acids deleted, substituted, or added in the amino acid sequence, having 95% or more, preferably 98% or more, more preferably 99% or more identity with the amino acid sequence. Things, etc. Here, "identity" means that when a gap is introduced into the two amino acid sequences or aligned (aligned) so as to have the highest degree of identity without introduction, the other to the total number of amino acid residues in one amino acid sequence, including the number of gaps. It refers to the ratio (%) of the number of identical amino acid residues in the amino acid sequence of In addition, "several" means an integer of 2 to 10, for example, an integer of 2 to 7, 2 to 5, 2 to 4, and 2 to 3. Specific examples of natural variants include variants based on polymorphisms such as SNP (monobase polymorphism), splice variants, and the like. It is preferable that the substitution is a conservative amino acid substitution. This is because conservative amino acid substitutions may have substantially the same structure or properties as the peptide having the amino acid sequence. Conservative amino acids are non-polar amino acids (glycine, alanine, phenylalanine, valine, leucine, isoleucine, methionine, proline, tryptophan) and polar amino acids (amino acids other than non-polar amino acids), charged amino acids (acidic amino acids (aspartic acid, glutamic acid)) and basic amino acids. Amino acids (arginine, histidine, lysine)) and uncharged amino acids (amino acids other than charged amino acids), aromatic amino acids (phenylalanine, tryptophan, tyrosine), branched amino acids (leucine, isoleucine, valine) and aliphatic amino acids (glycine, alanine, leucine) , Isoleucine, valine) and the like are known. In addition, it may include a peptide having increased structural stability to heat, pH, or the like of the peptide due to a mutation or modification in the amino acid sequence or increased peptide activity.

The present invention provides a composition for promoting hair growth comprising the peptide.

The composition of the present invention contains the peptide, and has excellent hair growth promoting ability, and thus can be used for promoting hair growth or preventing, improving, or treating hair loss, and the promotion of hair growth or hair loss prevention, improvement, and treatment are γδ T cell recruiting (recruiting ) Through the stimulation of the hair follicle cells, but not necessarily limited thereto, and the mechanism is not known in the art.

The composition of the present invention may be delivered by means of oral administration, parenteral administration, topical administration or modified release, but is not particularly limited thereto, and the peptide of the present invention promotes hair growth or prevents, treats, or improves hair growth. Any method can be chosen as long as it can be effectively communicated to.

The composition of the present invention may specifically be delivered by a transdermal absorption method, including, for example, cataplasmase or patch attachment, plaster attachment, microneedle patch attachment, transdermal injection injection, ointment or cream. Hair growth promotion or hair loss prevention, improvement, or delivery to the target area for treatment through a percutaneous absorption route by means of skin application in the form of emulsion or powder, spray (including aerosol form) spraying, etc., but is not particularly limited thereto, in this case Since the peptide of the present invention can be delivered more directly to the target site, efficient delivery is possible by preventing peptide activity denaturation in the delivery process, and the delivery speed can be relatively superior compared to other methods.

In the above oral administration, the composition of the present invention may be provided in a solid, semi-solid or liquid dosage form for oral administration. The oral administration also includes buccal, sublingual and sublingual administration. Suitable oral dosage forms include tablets, fast melts (quick-dissolving tablets), chewable tablets, capsules, pills, strips, troches, sugar tablets, pastilles, cachets, pellets, medicinal chewing gum, bulk powder, effervescent or Non-foaming powders or granules, oral mists, solutions, emulsions, suspensions, wafers, sprinkles, elixirs and syrups. In addition to the active ingredient(s), the compositions of the present invention can be used as binders, fillers, diluents, disintegrants, wetting agents, lubricants, lubricants, colorants, dye-migration inhibitors, sweeteners, flavoring agents, emulsifiers, suspending and dispersing agents, preservatives, solvents, non It may include one or more excipients including, but not limited to, aqueous liquids, organic acids, and carbon dioxide sources.

The binder or granulating agent imparts cohesiveness to the tablet so that the tablet is not damaged after compression. Suitable binders or granulating agents include starches such as corn starch, potato starch and pre-gelatinized starch (eg STARCH 1500 ^® ); gelatin; Sugars such as sugar, glucose, dextrose, molasses and lactose; Acacia, alginic acid, alginate, Irish moss extract, panwar gum, ghatti gum, mucus of isabgol husks, carboxymethylcellulose, methylcellulose, polyvinylpyrrolidone (PVP) ), natural or synthetic gums such as Veegum, larch arabgalactan, powdered trigacanth, and guar gum; Cellulose such as ethyl cellulose, cellulose acetate, carboxymethyl cellulose, methyl cellulose, hydroxyethylcellulose (HEC), hydroxypropylcellulose (HPC) and hydroxypropylmethyl cellulose (HPMC); AVICEL ^® CL-611, AVICEL ^® PH-101, AVICEL ^® PH-102, AVICEL ^® PH-103, AVICEL ^® PH-105, AVICEL ^® PH-112, AVICEL ^® PH-113, AVICEL ^® PH-200, AVICEL ^® microcrystalline cellulose, such as ^{PH-301, AVICEL ® PH-} 302, AVICEL ® RC-501, AVICEL ® RC-581, and AVICEL ^® RC-591; And mixtures thereof, but are not limited thereto. Suitable fillers include, but are not limited to, talc, calcium carbonate, microcrystalline cellulose, powdered cellulose, dextrate, kaolin, mannitol, silicic acid, sorbitol, starch, pre-gelatinized starch and mixtures thereof. The amount of the binder or filler in the composition of the present invention depends on the type of preparation, and can be readily recognized by those skilled in the art. The composition of the present invention may contain from about 50 to about 99% by weight of a binder or filler.

Suitable diluents include, but are not limited to, dicalcium phosphate, calcium sulfate, lactose, sorbitol, sucrose, inositol, cellulose, kaolin, mannitol, sodium chloride, dry starch and powdered sugar. Certain diluents, such as mannitol, lactose, sorbitol, sucrose and inositol, when present in sufficient amounts, can characterize some compressed tablets that allow disintegration in the oral cavity by chewing. These compressed tablets can be used as chewable tablets. The amount of the diluent in the composition of the present invention depends on the type of preparation, and can be readily recognized by those skilled in the art. The compositions of the present invention may contain from about 10 to about 99% by weight of a diluent.

Suitable disintegrants include agar; Bentonite; Cellulose such as methylcellulose and carboxymethyl cellulose; Wood products; Natural sponge; Cation exchange resin; Alginic acid; Gums such as guar gum and Veegum HV; Citrus pulp; Crosslinked cellulose such as croscarmellose; Crosslinked polymers such as crospovidone; Crosslinked starch; Calcium carbonate; Microcrystalline cellulose such as sodium starch glycolate; Polyacrylline potassium; Starches such as corn starch, potato starch, tapioca starch and pre-gelatinized starch; clay; Align; And mixtures thereof, but are not limited thereto. The amount of the disintegrant in the composition of the present invention varies depending on the type of preparation, and can be easily recognized by those skilled in the art. The composition of the present invention may contain from about 0.5 to about 15% by weight or from about 1 to about 5% by weight of a disintegrant.

Suitable lubricants include calcium stearate; Magnesium stearate; Mineral oil; Light mineral oil; glycerin; Sorbitol; Mannitol; Glycerol such as glycerol behenate and polyethylene glycol (PEG); Stearic acid; Sodium lauryl sulfate; Talc; Hardened vegetable oils including peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, corn oil and soybean oil; Zinc stearate; Ethyl oleate; Ethyl laurate; Agar; Starch; Lycopodium; Silica or silica gels, such as AEROSIL ^® 200 and CAB-O-SIL ^®; And mixtures thereof, but are not limited thereto. The amount of the lubricant in the composition of the present invention depends on the type of formulation and can be readily recognized by those skilled in the art. The compositions of the present invention may contain from about 0.1 to about 5% by weight of a lubricant.

Suitable lubricants include talc containing no colloidal silicon dioxide, CAB-O-SIL ^® and asbestos, but are not limited to. Suitable colorants include, but are not limited to, approved, certified, water soluble FD&C dyes, water insoluble FD&C dyes suspended on alumina hydrates, color lakes and mixtures thereof. Color lakes are the insoluble form of water-soluble dyes formed by adsorbing water-soluble dyes onto hydrous oxides of heavy metals. Suitable flavors include, but are not limited to, natural flavors derived from plants such as peppermint and methyl salicylate, and synthetic combinations of compounds that produce a pleasant taste sensation such as fruits. Suitable sweeteners include, but are not limited to, sucrose, lactose, mannitol, syrup, glycerin and artificial sweeteners such as saccharin and aspartame. Suitable emulsifiers are gelatin, acacia, tragacanth, bentonite, and interfaces such as polyoxyethylene sorbitan monooleate (TWEEN ^® 20), polyoxyethylene sorbitan monooleate 80 (TWEEN ^® 80) and triethanolamine oleate. Including, but not limited to, active agents. Suitable suspending and dispersing agents include, but are not limited to, sodium carboxymethyl cellulose, pectin, tragacanth, vegum, acacia, sodium carbomethylcellulose, hydroxypropyl methylcellulose and polyvinylpyrrolidone. Suitable preservatives include, but are not limited to, glycerin, methyl and propylparabens, benzoic acid, sodium benzoate and alcohols. Suitable wetting agents include, but are not limited to, propylene glycol monostearate, sorbitan monooleate, diethylene glycol monolaurate and polyoxyethylene laurylether. Suitable solvents include, but are not limited to, glycerin, sorbitol, ethyl alcohol and syrup. Suitable non-aqueous liquids for use in emulsions include, but are not limited to, mineral oil and cottonseed oil. Suitable organic acids include, but are not limited to, citric acid and tartaric acid. Suitable carbon dioxide sources include, but are not limited to, sodium bicarbonate and sodium carbonate.

It should be understood that many excipients can serve multiple functions even within the same formulation.

For oral administration, the compositions of the present invention may be provided as compressed tablets, pulverized tablets, chewable sugar tablets, fast dissolving tablets, multiple compressed tablets, enteric coated tablets or sugar coated or film coated tablets. Enteric coated tablets are compressed tablets coated with a substance that resists the action of gastric acid but dissolves or decomposes in the intestine to protect the active ingredient in the acidic environment of the stomach. Enteric coatings include, but are not limited to, fatty acids, fats, phenyl salicylate, waxes, shellac, ammonated shellac and cellulose acetate phthalate. Sugar coated tablets are compressed tablets surrounded by a sugar coating, which may be useful to mask an unpleasant taste or odor and to protect the active ingredient or excipient in the tablet from oxidation. Film coated tablets are compressed tablets covered with a thin layer or film of a water-soluble material. Film coatings include, but are not limited to, hydroxyethylcellulose, sodium carboxymethylcellulose, polyethylene glycol 4000 and cellulose acetate phthalate. Film coatings impart the same general properties as sugar coatings. Multiple compressed tablets are compressed tablets made by one or more compression cycles, including layered tablets and press coated or dry coated tablets.

Tablet dosage forms may contain the active ingredient(s) in powder, crystalline or granular form, alone or with binders, disintegrants, controlled-release polymer lubricants, diluents and/or coloring agents. Flavors or sweeteners are particularly useful in the formation of chewable tablets or lozenges.

For oral administration, the compositions of the present invention may be presented as soft or hard capsules which may be made of gelatin, methyl cellulose, starch or calcium alginate. Hard gelatin capsules, also known as dry fill capsules (DFC), are made up of two sections, one sliding over the other, completely enclosing one active ingredient. Soft elastic capsules (SEC) are soft, spherical shells such as gelatin shells plasticized by the addition of glycerin, sorbitol or similar polyols. Soft gelatin shells may contain preservatives to prevent the growth of microorganisms. Suitable preservatives are those described herein including methyl- and propyl-parabens and sorbic acid. Liquid, semi-solid and solid dosage forms provided herein can be encapsulated within capsules. Suitable liquid and semi-solid dosage forms include solutions and suspensions in propylene carbonate, vegetable oils or triglycerides. Capsules containing such solutions are described in US Pat. Nos. 4,328,245; 4,409,239; And 4,410,545. Capsules can also be coated as known to those of skill in the art to modify or maintain dissolution of the active ingredient(s).

For oral administration, the compositions of the present invention may be provided in liquid or semi-solid dosage forms including emulsions, solutions, suspensions, elixirs and syrups. An emulsion is a two-stage system in which one liquid is dispersed in the form of small spheres through another liquid, which can be oil-in-water or water-in-oil. Emulsions may contain non-aqueous liquids or solvents, emulsifiers and preservatives. Suspensions may contain suspending agents and preservatives. Alcoholic aqueous solutions include acetals, such as di(lower alkyl)acetals of lower alkyl aldehydes, such as acetaldehyde di ethyl acetal; And water-miscible solvents having one or more hydroxyl groups such as propylene glycol and ethanol. Elixir is a clear, sweet, aqueous alcoholic solution. Syrup is a concentrated aqueous solution of sugars such as sugar, and may also contain preservatives. In the case of liquid dosage forms, for example, a solution in polyethylene glycol can be conveniently measured for administration by diluting it with a sufficient amount of a liquid carrier, for example water.

Other useful liquid and semi-solid dosage forms include compositions of the present invention and those containing dialkylated mono- or poly-alkylene glycols including 1,2-dimethoxymethane, diglyme, triglide, tetraglyme. Including, but not limited to. Polyethylene glycol -550-dimethyl ether, polyethylene glycol -750-dimethyl ether (where "350", "550" and "750" each obtained polyethylene glycol of approximately number average molecular weight (Mn). These dosage forms are butylated. Hydroxy toluene (BHT), butylated hydroxy anisole (BHA), propyl gallate, vitamin E, hydroquinone, hydroxycoumarin, ethanolamine, lecithin, cephalin, ascorbic acid, maleic acid, sorbitol, phosphoric acid , Bissulfite, sodium metasulfite, thiodipropionic acid and esters thereof, and dithiocarbamate.

For oral administration, the compositions of the present invention may also be provided in the form of liposomes, micelles, microspheres or nanosystems. Micelle dosage forms can be prepared as described in US Pat. No. 6,350,458.

For oral administration the compositions of the present invention may be provided as non-foaming or effervescent, granules or powders to be reconstituted into liquid dosage forms. Excipients used in non-foaming granules or powders may include diluents, sweetening and/or wetting agents. Excipients used in the effervescent granules or powders include a source of organic acids and carbon dioxide.

Colorants and fragrances can be used in all dosage forms described herein.

For oral administration the compositions of the present invention may be formulated in immediate or modified release dosage forms including delayed-, sustained-, pulsed-, controlled-, targeted- and programmed release forms.

The compositions of the present invention may be administered parenterally by injection, infusion or implantation for local or systemic administration. Parenteral administration herein includes intravenous, intraarterial, intraperitoneal, intrathecal, intraventricular, intraurethral, intrasternal, intracranial, intramuscular, intrasynovial, intraluminal and subcutaneous administration.

For parenteral administration, the compositions of the present invention may be prepared in any dosage form suitable for parenteral administration, including solutions, suspensions, emulsions, micelles, liposomes, microspheres, nanosystems and solid forms suitable for solutions or suspensions of liquids prior to injection. It can be formulated. Such dosage forms can be prepared according to conventional methods known to those skilled in the art (Remington: The Science and Practice of Pharmacy, supra).

Compositions for parenteral administration include aqueous vehicles, water-miscible vehicles, non-aqueous vehicles, antimicrobial agents or preservatives against the growth of microorganisms, stabilizers, solubility enhancers, isotonic agents, buffers, antioxidants, local anesthetics, suspending and dispersing agents. , A wetting or emulsifying agent, a complexing agent, a sequestering or chelating agent, a cryoprotectant, a leveling agent, a thickening agent, a pH adjusting agent, an inert gas, and one or more excipients, including but not limited thereto.

Suitable aqueous vehicles include, but are not limited to, water, saline, physiological saline or phosphate buffered saline (PBS), sodium chloride injection, Ringer's injection, isotonic dextrose injection, sterile water injection, and dextrose and lactate Ringer's injection. Suitable non-aqueous vehicles include fixed oils of vegetable origin, castor oil, corn oil, cottonseed oil, olive oil, peanut oil, mentha oil, safflower oil, sesame oil, soybean oil, hydrogenated vegetable oil, hydrogenated soybean oil, medium chain triglycerides of coconut oil, seed oil. It is not limited thereto. Suitable water-miscible vehicles are ethanol, 1,3-butanediol, liquid polyethylene glycols (e.g. polyethylene glycol 300 and polyethylene glycol 400), propylene glycol, glycerin, N-methyl-2-pyrrolidone, N,N-dimethylacetamide. And dimethylsulfoxide, but is not limited thereto.

Suitable antimicrobial agents or preservatives are phenol, cresol, mercury, benzyl alcohol, chlorobutanol, methyl and propyl p-hydroxybenzoate, thimerosal, benzalkonium chloride (e.g. benzethonium chloride), methyl- and propyl-parabens, And, including, but not limited to, sorbic acid. Suitable tonicity agents include, but are not limited to, sodium chloride, glycerin and dextrose. Suitable buffering agents include, but are not limited to, phosphate and citrate. Suitable antioxidants are those described herein including bisulfite and metaba sulfite sodium. Suitable local anesthetics include, but are not limited to, procaine hydrochloride. Suitable suspending and dispersing agents are those described herein including sodium carboxymethylcellulose, hydroxypropyl methylcellulose and polyvinylpyrrolidone. Suitable emulsifiers are those described herein including poly oxyethylene sorbitan monolaurate, polyoxyethylene sorbitan monooleate 80 and triethanolamine oleate. Suitable sequestering or chelating agents include, but are not limited to, EDTA. Suitable pH adjusters include, but are not limited to, sodium hydroxide, hydrochloric acid, citric acid and lactic acid. Suitable complexing agents are cyclodextrins including α-cyclodextrin, β-cyclodextrin, hydroxypropyl-β-cyclodextrin, sulfoxy butylether-β-cyclodextrin and sulfobutylether 7-β-cyclodextrin (CAPTISOL ^® ). Including, but not limited to, dextrin.

When the composition of the present invention is administered in multiple doses, the multiple dose parenteral formulation should contain a bacteriostatic or fungal-removing concentration of an antimicrobial agent. All parenteral formulations should be sterile as known and practiced in the art.

Compositions for parenteral administration may be provided as ready-to-use sterile solutions. In another embodiment, the composition of the present invention is provided as a sterile, dry soluble product comprising a lyophilized powder or subcutaneous tablet to be reconstituted with a vehicle prior to use. In another embodiment, the composition of the present invention is provided as a ready-to-use sterile suspension. In another embodiment, the compositions of the present invention are provided as sterile, dry insoluble products that are reconstituted with a vehicle prior to use. In another embodiment, the composition of the present invention is provided as a ready-to-use sterile emulsion.

The compositions of the invention provided herein for parenteral administration can be formulated as immediate or modified release dosage forms including delayed-, sustained-, pulsed-, controlled-, targeted- and programmed release forms.

For parenteral administration, the compositions of the present invention may be formulated as a suspension, solid, semi-solid or thixotropic liquid for administration as an implanted reservoir. In one embodiment, the composition of the present invention is dispersed in a solid inner matrix surrounded by an outer polymeric membrane that is insoluble in body fluids but allows the active ingredient(s) in the composition to pass.

Suitable inner matrices are polymethylmethacrylate, polybutyl-methacrylate, plasticized or non-fired polyvinylchloride, plasticized nylon, plasticized polyethylene terephthalate, natural rubber, polyisoprene, polyisobutylene, polybutadiene, Polyethylene, ethylene-vinyl acetate copolymer, silicone rubber, polydimethylsiloxane, silicone carbonate copolymer, hydrophilic polymers, for example hydrogels of esters of acrylic and methacrylic acid, collagen, crosslinked polyvinyl alcohol and crosslinked Includes, but is not limited to, partially hydrolyzed polyvinyl acetate.

Suitable outer polymer membranes are polyethylene, polypropylene, ethylene/propylene copolymer, ethylene/ethyl acrylate copolymer, ethylene/vinyl acetate copolymer, silicone rubber, polydimethyl siloxane, neoprene rubber, chlorinated polyethylene, polyvinylchloride, vinyl acetate, Vinylidene chloride, vinyl chloride copolymer with ethylene and propylene, ionomer polyethylene terephthalate, butyl rubber epichlorohydrin rubber, ethylene/vinyl alcohol copolymer, ethylene/vinylacetate/vinyl alcohol terpolymer, and ethylene/vinyl Including, but not limited to, oxyethanol copolymer.

The composition of the present invention can be topically administered to the skin, pores or mucous membranes. Local administration herein includes intradermal (intra), intraconjunctival, intracorneal, intraocular, intraocular, transdermal, nasal, vaginal, urethral, respiratory and rectal administration.

Compositions of the present invention include emulsions, solutions, suspensions, creams, gels, hydrogels, ointments, powders, dressings, elixirs, lotions, suspensions, tinctures, pastes, foams, films, aerosols, irrigation, sprays, suppositories, bandages and skin patches. It can be formulated in any dosage form suitable for topical administration for local or systemic effects, including. Topical formulations of the compositions of the present invention may also include liposomes, micelles, microspheres, nanosystems and mixtures thereof.

Carriers and excipients suitable for use in the topical formulations provided herein are aqueous vehicles, water-miscible vehicles, non-aqueous vehicles, antimicrobial agents or preservatives against the growth of microorganisms, stabilizers, solubility enhancers, isotonic agents, buffers, oxidizing agents. Including, but not limited to, inhibitors, local anesthetics, suspending and dispersing agents, wetting or emulsifying agents, complexing agents, sequestering or chelating agents, penetration enhancing agents, anti-freezing agents, smoothing agents, thickening agents, pH adjusting agents, and inert gases.

The compositions of the present invention can also be administered topically by electroporation, iontophoresis, sonophoresis, ultrasound transduction, or microneedle or needle-free injection methods such as POWDERJECT ^™ and BIOJECT ^™ .

The composition of the present invention may be provided in the form of ointments, creams and gels. Suitable ointments include oily or hydrocarbon vehicles including lard, benzoin lard, olive oil, cottonseed oil and white petrolatum; Emulsifying or absorbing vehicles such as hydrophilic petrolatum, hydroxystearin sulfate and anhydrous lanolin; Moisture-removable vehicles such as hydrophilic ointments; Water-soluble ointments comprising polyethylene glycols of various molecular weights; Emulsion vehicles, either water-in-oil (W/O) or oil-in-water (O/W) emulsions containing cetyl alcohol, glyceryl mono stearate, lanolin and stearic acid (Remington: The Science and Practice of Pharmacy, supra). These vehicles are emollients, but usually antioxidants and preservatives must be added.

Suitable cream bases may be oil-in-water or water-in-oil. Suitable cream vehicles are washable with water and may contain an oil phase, an emulsifier and an aqueous phase. The oil phase is also referred to as the "internal" phase, which generally includes fatty acids such as petrolatum and cetyl or stearyl alcohol. Not necessarily, but typically the volume of the aqueous phase exceeds the oil phase and generally contains a moisturizer. Emulsifiers in cream formulations can be nonionic, anionic, cationic or amphoteric surfactants.

Gels are semi-solid, suspension systems. Single-phase gels contain organic macromolecules distributed substantially evenly throughout the liquid carrier. Suitable gelling agent is an acrylic acid polymer cross-linked, such as carbomer, carboxy polyalkylene and CARBOPOL ^®; Hydrophilic polymers such as polyethylene oxide, polyoxyethylene-polyoxypropylene copolymer and polyvinyl alcohol; Cellulosic polymers such as hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl methylcellulose phthalate, and methyl cellulose; Gums such as tragacanth and xanthan gum; Sodium alginate; And gelatin, but is not limited thereto. To prepare a homogeneous gel, a dispersing agent such as alcohol or glycerin may be added, or the gelling agent may be dispersed by grinding, mechanical mixing and/or stirring.

The composition of the present invention is a suppository, pessary, bougy, poultice or poultice, paste, powder, dressing, cream, cast, contraceptive, study, solution, emulsion, suspension, tampon, gel, foam, spray Alternatively, it may be administered to the rectum, urethra, vagina, or peri-vaginal in the form of an enema. Such dosage forms can be prepared using conventional methods described in Remington: The Science and Practice of Pharmacy, supra.

Rectal, urethral and vaginal suppositories are solids for insertion into body orifices that are solid at room temperature but melt or soften at body temperature to release the active ingredient(s) inside the orifice. Carriers used in rectal and vaginal suppositories include bases or vehicles such as adjuvants that create a melting point near body temperature; And antioxidants described herein including bisulfite and metabisulfite sodium. Suitable vehicles are cocoa butter (theo broma oil), glycerin-gelatin, carbo wax (polyoxyethylene glycol), spermaceti, paraffin, white and yellow waxes and suitable mixtures of mono-, di- and triglycerides of fatty acids. And hydroxy gels such as polyvinyl alcohol, hydroxyethyl methacrylate, and polyacrylic acid, but are not limited thereto; Combinations of various carriers may also be used. Rectal and vaginal suppositories can be compressed or molded and compressed. Typical weights for rectal and vaginal suppositories are about 2 to about 3 grams.

The compositions of the present invention can be administered ophthalmically in the form of solutions, suspensions, ointments, emulsions, gel-forming solutions, solution powders, gels, ocular inserts and implants.

The composition of the present invention can be administered intranasally or by inhalation into the respiratory tract. The composition of the present invention is a pressurized vessel, a pump, a nebulizer, such as a nebulizer, such as a nebulizer that uses electrohydrodynamics to create a fine mist, alone or 1,1,1,2-tetrafluoroethane or 1, It can be provided in the form of an aerosol or solution for delivery using with a suitable propellant such as 1,1,2,3,3,3- heptafluoro propane. The composition of the present invention can also be used alone or in combination with an inert carrier such as lactose or phospholipid as a dry powder for ventilation; And it can be provided as a nasal drops. For intranasal use, the powder may contain biological adhesives including chitosan or cyclodextrin.

Solutions or suspensions for use in pressurized vessels, pumps, nebulizers, nebulizers or nebulizers may include ethanol, aqueous ethanol or suitable alternative agent(s) for dispersing, solubilizing or extending release of the active ingredient; Propellant as a solvent; And/or a surfactant such as sorbitan trioleate, oleic acid or oligolactic acid.

The compositions of the present invention may be micronized to a size suitable for delivery by inhalation, such as about 50 micrometers or less, or about 10 micrometers or less. Particles of this size can be prepared using grinding methods known to those skilled in the art such as spiral jet milling, fluid bed jet milling, supercritical fluid treatment to form nanoparticles, high pressure homogenization or spray drying.

Capsules, blisters and cartridges for use in an inhaler or injector comprise a powder mixture of the composition of the present invention; Suitable powder bases such as lactose or starch; And performance modifiers such as l-leucine, mannitol or magnesium stearate. Lactose may be anhydrous or in the form of a monohydrate. Other suitable excipients or carriers include, but are not limited to, dextran, glucose, maltose, sorbitol, xylitol, fructose, sucrose and trehalose. For inhalation/intranasal administration the compositions of the present invention may contain suitable fragrances such as menthol and levomenthol; And/or a sweetener such as saccharin and saccharin sodium.

For topical administration the compositions of the present invention may be formulated for immediate release or modified release including delayed release, sustained release, pulsed release, controlled release, targeted release and programmed release.

The composition of the present invention can be formulated in a modified release dosage form. The term “modified release” as used herein refers to a dosage form in which the rate or location of release of the active ingredient(s) when administered by the same route differs from the rate or location of release of the immediate dosage form. Modified release forms include, but are not limited to, delayed, extended, sustained, pulsatile, controlled, accelerated and rapid, targeted, programmed release and gastrointestinal maintenance. Compositions of the present invention in modified release dosage forms include, but are limited to, matrix controlled release devices, osmotic pressure controlled release devices, multi-particle controlled release devices, ion exchange resins, enteric coatings, multilayer coatings, microspheres, liposomes, and combinations thereof. It doesn't work. The release rate of the active ingredient(s) can also be altered by changing the particle size and polymorph of the active ingredient(s).

Examples of modified release are described in U.S. Patent 3,845,770; 3,916,899; 3,536,809; 3,598,123; 4,008,719; 5,674,533; 5,059,595; 5,591,767; 5,120,548; 5,073,543; 5,639,476; 5,354,556; 5,639,480; 5,733,566; 5,739,108; 5,891,474; 5,922,356; 5,958,458; 5,972,891; 5,980,945; 5,993,855; 6,045,830; 6,087,324; 6,113,943; 6,197,350; 6,248,363; 6,264,970; 6,267,981; 6,270,798; 6,375,987; 6,376,461; 6,419,961; 6,589,548; 6,613,358; 6,623,756; 6,699,500; 6,793,936; 6,827,947; 6,902,742; 6,958,161; 7,255,876; 7,416,738; 7,427,414; 7,485,322; Bussemer et al ., Crit. Rev. Ther. Drug Carrier Syst. 2001, 18, 433-458; Modified-Release Drug Delivery Technology, supra; Maroni et al ., Expert. Opin. Drug Deliv. 2005, 2855-871; Shi et al ., Expert Opin. Drug Deliv. 2005, 2, 1039-1058; Polymers in Drug Delivery; Ijeoma et al ., Eds.; CRC Press: 2006; Badawy et al ., J. Pharm. Sci. 2007, 9948-959; Conway, Recent Pat. Drug Deliv. Formul. 2008, 2, 1-8; Gazzaniga et al ., Eur. J. Pharm. Biopharm. 2008, 68, 11-18; Nagarwal et al ., Curr. Drug Deliv. 2008, 5282-289; Gallardo et al ., Pharm. Dev. Technol. 2008, 13413-423; Chrzanowski, AAPS PharmSciTech. 2008, 9635-638; Chrzanowski, AAPS PharmSciTech. 2008, 9639-645; Kalantzi et al ., Recent Pat. Drug Deliv. Formul. 2009, 3, 49-63; Saigal et al ., Recent Pat. Drug Deliv. Formul. 2009, 3, 64-70; and Roy et al, J. Control Release 2009, 134, 74 -. 80 include those described in but is not limited thereto.

The present invention provides a pharmaceutical composition for promoting hair growth or preventing or treating hair loss comprising the peptide.

The pharmaceutical composition for promoting hair growth or preventing or treating hair loss comprising the peptide of the present invention may further include a pharmaceutically acceptable carrier, and may be formulated together with the carrier. In the present invention, the term'pharmaceutically acceptable carrier' refers to a carrier or diluent that does not stimulate an organism and does not inhibit the biological activity and properties of the administered compound. Acceptable pharmaceutical carriers for compositions formulated as liquid solutions are sterilized and biocompatible, and include saline, sterile water, Ringer's solution, buffered saline, albumin injection solution, dextrose solution, maltodextrin solution, glycerol, ethanol, and One or more of these components may be mixed and used, and other conventional additives such as antioxidants, buffers, and bacteriostatic agents may be added as necessary. In addition, diluents, dispersants, surfactants, binders, and lubricants may be additionally added to prepare injectable formulations such as aqueous solutions, suspensions, emulsions, etc., pills, capsules, granules, or tablets.

The pharmaceutical composition of the present invention can be applied to any formulation containing the peptide of the present invention as an active ingredient, and can be prepared in an oral or parenteral formulation. Specific formulations include oral, rectal, nasal, topical (including cheek and sublingual), subcutaneous, vaginal or parenteral; intramuscular, subcutaneous and intravenous Including) may include a form suitable for administration or a form suitable for administration by inhalation or infusion, but is not limited thereto.

The pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount. The effective dose level depends on the patient's disease type, severity, drug activity, drug sensitivity, time of administration, route of administration and rate of excretion, duration of treatment, factors including concurrent drugs and other factors well known in the medical field. Can be determined. The pharmaceutical composition of the present invention may be administered as an individual therapeutic agent or administered in combination with other therapeutic agents, may be administered sequentially or simultaneously with a conventional therapeutic agent, and may be administered single or multiple. It is important to administer an amount capable of obtaining the maximum effect in a minimum amount without side effects in consideration of all the above factors, and this can be easily determined by a person skilled in the art.

The dosage of the pharmaceutical composition of the present invention varies greatly depending on the patient's weight, age, sex, health condition, diet, administration time, administration method, excretion rate, and severity of disease, and the appropriate dosage is, for example. It may vary depending on the amount of drug accumulated in the patient's body and/or the specific efficacy of the peptide of the present invention used. In general, it can be calculated based on the EC50 measured to be effective in an in vivo animal model and in vitro , for example, 0.01 μg to 1 g per 1 kg of body weight, daily, weekly, In a monthly or annual unit period, the administration may be divided once or several times per unit period, or may be continuously administered for a long period of time using an infusion pump. The number of repeated administrations is determined in consideration of the duration of the drug and the concentration of the drug in the body. The composition may be administered for recurrence even after treatment is performed according to the course of the disease treatment.

The pharmaceutical composition of the present invention may further contain at least one active ingredient exhibiting the same or similar function in relation to promoting hair growth or preventing or treating hair loss, or a compound that maintains/increases the solubility and/or absorption of the active ingredient. have. In addition, optionally, a chemotherapeutic agent, an anti-inflammatory agent, an antiviral agent and/or an immunomodulatory agent may be further included.

In addition, the pharmaceutical compositions of the present invention may be formulated using methods known in the art to provide rapid, sustained or delayed release of the active ingredient after administration to a mammal. The formulation may be in the form of a powder, granule, tablet, emulsion, syrup, aerosol, soft or hard gelatin capsule, sterile injectable solution, or sterile powder.

The present invention provides a cosmetic composition for promoting hair growth or preventing or improving hair loss comprising the peptide.

When the composition of the present invention is prepared as a cosmetic composition, the composition of the present invention may include not only the peptide, but also components commonly used in cosmetic compositions, such as antioxidants, stabilizers, solubilizers, vitamins, pigments, and It may include conventional adjuvants such as perfume, and a carrier.

Products to which the composition can be added include cosmetics such as astringent lotion, softening lotion, nutrient lotion, various creams, essences, packs, and foundations, and cleansing, face wash, soap, treatments, and essences. , Is not limited thereto.

Specific formulations of the cosmetic composition of the present invention include skin lotion, skin softener, skin toner, astringent, lotion, milk lotion, moisture lotion, nutrition lotion, massage cream, nutrition cream, moisture cream, hand cream, essence, nutrition essence, pack, Soap, shampoo, cleansing foam, cleansing lotion, cleansing cream, body lotion, body cleanser, emulsion, lipstick, makeup base, foundation, press powder, loose powder, eye shadow, conditioner, gel, wax, mist, etc. However, it is not necessarily limited thereto.

The composition may be formulated by stabilizing the peptide by containing it inside the nanoliposome. When the peptide is contained inside the nanoliposome, the components of the peptide are stabilized and problems such as precipitation formation and transformation can be solved during formulation, and the solubility and transdermal absorption of the component can be increased to maximize the efficacy expected from the peptide. Can be expressed.

The present invention provides a health functional food for promoting hair growth or preventing or improving hair loss comprising the peptide.

The health functional food of the present invention can be manufactured and processed into foods in the form of tablets, capsules, powders, granules, liquids, pills, etc. for the purpose of preventing or improving peripheral nerve diseases.

The health functional food of the present invention may be manufactured and processed using raw materials or ingredients having useful functions for the human body according to the Health Functional Food Act No.6727, which is a nutrient for the structure and function of the human body. It refers to ingestion for the purpose of controlling or obtaining beneficial effects for health purposes such as physiological effects.

The health functional food of the present invention may contain ordinary food additives, and whether it is suitable as a food additive is determined according to the general rules and general test methods for food additives approved by the Food and Drug Administration, unless otherwise specified. It is judged according to standards and standards.

Examples of the items listed in the food additive process include chemical compounds such as ketones, glycine, calcium citrate, nicotinic acid, and cinnamic acid; Natural additives such as reduced pigment, licorice extract, crystalline cellulose, high color pigment, and guar gum; It includes, but is not limited to, mixed preparations such as a sodium L-glutamate preparation, an alkali additive for noodles, a preservative preparation, and a tar color preparation.

For example, in the health functional food in the form of a tablet, a mixture obtained by mixing the peptide of the present invention with an excipient, a binder, a disintegrant, and other additives is granulated by a conventional method, and then a lubricant is added thereto and compression molding, or the mixture Can be directly compression molded. In addition, the health functional food in the form of a tablet may contain a mating agent or the like, if necessary.

Among the capsule-type health functional foods, hard capsules can be prepared by filling a mixture of the peptides of the present invention into an ordinary hard capsule with additives such as excipients, and soft capsules mixing the peptides of the present invention with additives such as excipients. One mixture can be prepared by filling a capsule base such as gelatin. The soft capsules may contain a plasticizer such as glycerin or sorbitol, a colorant, a preservative, and the like, if necessary.

The cyclic health functional food can be prepared by molding a mixture of the peptide of the present invention, an excipient, a binding agent, a disintegrant, etc., by a conventionally known method, and can be coated with a white sugar or other coating agent if necessary. Alternatively, the surface may be coated with a material such as starch or talc.

The health functional food in the form of a granule can be prepared in granular form by a mixture of the peptide of the present invention, an excipient, a binder, a disintegrant, etc. by a conventionally known method, and may contain a flavoring agent, a flavoring agent, etc., if necessary. have.

The health functional foods are beverages, meat, chocolate, foods, sweets. It may be pizza, ramen, other noodles, gums, candy, ice cream, alcoholic beverages, vitamin complexes, and health supplements.

The hair loss may belong to any of the causes without particular limitation, as long as the number of hairs exceeds the normal hair growth level and the number of hairs is less than the general number, specifically, adult hair loss, intermittent hair loss, neurogenic hair loss, tricotillomania , Malignant hair loss, non-rigid hair loss, seborrheic hair loss, pediatric hair loss, male type 　 alopecia, female type 　 hair loss, circular 　 alopecia 　 and at least one selected from the group consisting of telogen 　 hair loss.

More specifically, the hair loss is circular hair loss, hereditary androgen hair loss, telogen hair loss, traumatic hair loss, hair growth wall, pressure hair loss, growth stage hair loss, non-rigid hair loss, syphilis hair loss, seborrheic hair loss, symptomatic hair loss, scarring hair loss and congenital hair loss. It may be at least one selected from the group consisting of hair loss.

There is no particular limitation as hair that is the target of promoting hair growth or preventing, improving, or treating hair loss, but specifically, it may be at least one from the group consisting of body hair, hair, eyebrows, eyelashes, pubic hair, nose hair, and beard.

Hereinafter, examples will be described in detail to illustrate the present invention in detail.

Hereinafter, the peptide consisting of the amino acid sequence of SEQ ID NO: 1 is'DPS-4', the peptide consisting of the amino acid sequence of SEQ ID NO: 2 is'DPS-5', and the peptide consisting of the amino acid sequence of SEQ ID NO: 3 is'DPS-8'. Each can be abbreviated.

Example 1. Experimental method

As an experimental animal of the present invention, 40 days old C57BL/6 mice were purchased from Nara Biotech Co., Ltd., and after being purified for about 10 days, healthy animals were tested. During the experiment, the breeding environment conditions were kept at a temperature of 21-25℃, relative humidity of 45-65%, and lighting time for 12 hours. Feed and drinking water were fed freely.

The back skin hair of a 50-day-old mouse whose hair entered the resting period was first epilated using a clipper, and then a second epilation was performed using Body Nature Rosehip Oil Depilatory Cream. After 24 hours of hair removal, mice with similar characteristics such as weight and size were divided into 4 groups of 7 animals each, and then individually reared to measure the degree of hair growth.

50 μg of a peptide consisting of the amino acid sequence of SEQ ID NO: 1 (DPS-4), 50 μg of a peptide consisting of the amino acid sequence of SEQ ID NO: 2 (DPS-5), and a peptide consisting of the amino acid sequence of SEQ ID NO: 3 (DPS-8, EDCS) A solution each of which was dissolved in dimethyl sulfoxide (Sigma), acetone (Merck), and glycerol (Biopure) was applied to the skin of a mouse once at the same time for 2 weeks. A solution containing dimethyl sulfoxide (Sigma), acetone (Merck), and glycerol (Biopure) was set as a negative control, and 100 ㎍ tofacitinib citrate (Sigma), acetone (Merck), and glycerol (Biopure) dissolved in dimethyl sulfoxide (Sigma). The solution containing the was evaluated by placing it as a positive control group, and the composition of the coating solution is shown in Table 1 below.

After that, the back skin tissue of the mouse corresponding to the hair grown after 7 and 14 days at the epilation site was stained with hematoxylin & eosin to confirm the hair growth cycle and the presence of hair follicles.

group Acetone (μl) Glycerol (μl) division Negative control 150 30 DMSO 20 μl Positive control 150 30 5 mg/ml Tofacitinib citrate 20 μl DPS-4 150 30 5 mg/ml DPS-4 10 μl DPS-5 150 30 5 mg/ml DPS-5 10 μl DPS-8 150 30 5 mg/ml DPS-8 10 μl

Example 2. Evaluation of appearance of hair growth promoting efficacy

1 is a negative control group, a positive control group, an experimental group treated with a peptide consisting of the amino acid sequence of SEQ ID NO: 1 (DPS-4), a peptide consisting of the amino acid sequence of SEQ ID NO: 2 (DPS-5) and the amino acid sequence of SEQ ID NO: 3 You can see the appearance picture of the hair growth degree of the experimental group treated with the formed peptide (DPS-8). Referring to this, the degree of hair growth when the peptides of the present invention (DPS-4, DPS-5) were treated compared to the negative control group. It can be seen that is remarkably high, and it can be seen that the degree of growth is significantly higher than that of the positive control group treated with Tofacitinib. On the other hand, in the case of the experimental group treated with the peptide (DPS-8) consisting of the amino acid sequence of SEQ ID NO: 3, it can be confirmed that the degree of growth of the hair is very insignificant so that no significant difference from the degree of hair growth of the negative control group is shown.

Example 3. Histological evaluation of hair growth promoting efficacy

2 is a negative control group, a positive control group, an experimental group treated with a peptide consisting of the amino acid sequence of SEQ ID NO: 1 (DPS-4), a peptide consisting of the amino acid sequence of SEQ ID NO: 2 (DPS-5) and the amino acid sequence of SEQ ID NO: 3 The result of histological observation of the hair growth degree of the experimental group treated with the composed peptide (DPS-8) can be confirmed. Referring to this, compared to the negative control group, the peptides of the present invention (DPS-4, DPS-5) were treated. In this case, it can be seen that the degree of growth is significantly higher than that of the control group in terms of the overall length and thickness of the hair grown in the dyed area. However, in the case of the experimental group treated with the peptide (DPS-8) consisting of the amino acid sequence of SEQ ID NO: 3, it can be confirmed that the degree of growth of the hair is very insignificant such that no significant difference from the growth degree of the negative control group is shown.

The above experiment confirmed the excellent hair growth promoting effect of the peptide of the present invention in vivo , suggesting that it can be used as an excellent hair growth promoter.

<110> GENECELLPHARM <120> COMPOSITION FOR PROMOTING HAIR GROWTH <130> 18P10020 <160> 3 <170> KoPatentIn 3.0 <210> 1 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> DPS-4 <400> 1 Cys Leu Glu Tyr Phe Lys Gly Ala Ile Pro Leu Arg Lys 1 5 10 <210> 2 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> DPS-5 <400> 2 Lys Arg Val Lys Asn Ala Val Lys Tyr Leu Gln 1 5 10 <210> 3 <211> 4 <212> PRT <213> Artificial Sequence <220> <223> DPS-8 <400> 3 Glu Asp Cys Ser One

Claims (5)

Peptide consisting of the sequence of SEQ ID NO: 2.
A composition for promoting hair growth comprising a peptide consisting of the sequence of SEQ ID NO: 1 or 2.
A pharmaceutical composition for promoting hair growth comprising a peptide consisting of the sequence of SEQ ID NO: 1 or 2.
Cosmetic composition for promoting hair growth comprising a peptide consisting of the sequence of SEQ ID NO: 1 or 2.
Health functional food for promoting hair growth comprising a peptide consisting of the sequence of SEQ ID NO: 1 or 2.

Images